Logo

PTC Therapeutics Reports the US FDA’s Accelerated Approval of its Gene Therapy for AADC Deficiency

Share this
PTC Therapeutics 

PTC Therapeutics Reports the US FDA’s Accelerated Approval of its Gene Therapy for AADC Deficiency

Shots:

  • PTC Therapeutics’ brain-administered gene therapy has received the US FDA’s accelerated approval for AADC deficiency. The company also received a Rare Disease Priority Review Voucher, which it will monetize
  • Approval was based on data from the ongoing PTC-AADC-GT-002 trial, with a confirmatory long-term follow-up planned. It will be commercialized across the US for children & adults under the brand name, Kebilidi (eladocagene exuparvovec-tneq), with preparations underway
  • Kebilidi is a rAAV2-based gene therapy developed to transfer a functioning DDC gene to the putamen, boosting AADC enzyme levels and restoring dopamine production

Ref: PTC Therapeutics | Image: PTC Therapeutics

Related News:- PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

 

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions